# lamivudine = 3tc

### notes
+ prescription under medical supervision

### therapeutic action
+ antiretroviral, hiv-1 and hiv-2 nucleoside reverse transcriptase inhibitor

### indications
+ hiv-1 or hiv-2 infection, in combination with other antiretroviral drugs

### presentation
+ 150 mg and 300 mg tablets
+ 50 mg/5 ml oral solution

### dosage
+ child under 1 month: 4 mg/kg/day in 2 divided doses
+ child from 1 month to 12 years: 8 mg/kg/day in 2 divided doses
+ adult: 300 mg once daily or in 2 divided doses

| weight      | 10 mg/ml oral solution | 150 mg tablet | 300 mg tablet |
|-------------|------------------------|---------------|---------------|
| 5 to 9 kg   | 2.5 ml x 2             |               |               |
| 10 to 14 kg | 5 ml x 2               |               |               |
| 15 to 19 kg | 7 ml x 2               | ½ tab x 2     |               |
| 20 to 24 kg | 9 ml x 2               | ½ tab x 2     |               |
| 25 to 29 kg | 11 ml x 2              | 2 tab         | 1 tab         |
| ≥ 30 kg     | -                      | 2 tab         | 1 tab         |

### duration
+ the duration of treatment depends on the efficacy and tolerance of lamivudine.

### contra-indications, adverse effects, precautions
+ administer with caution to patients with history of hepatic disorders.
+ may cause: gastrointestinal disturbances (diarrhoea, nausea, vomiting, etc.) and possibly: haematological disorders, especially when combined with zidovudine (neutropenia, anaemia, thrombocytopenia), myopathy, hepatic or pancreatic disorders.
+ reduce dosage in patients with renal impairment.
+ *pregnancy*: no contra-indication

### remarks
+ for prophylactic treatment to reduce mother-to-child hiv transmission, check national recommendations.
+ many fixed-dose combinations containing lamivudine are available.
+ storage: below 25°c
+ once opened, oral solution keeps for 30 days maximum.